Tarsus Pharmaceuticals, Inc.
TARS
Pozycja w akcjach
#4623
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Cena akcji
$70.43
Kapitalizacja rynkowa
$3.30B
Zmiana (1 dzień)
3.46%
Zmiana (1 rok)
-3.43%
Kraj
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategoria
Healthcare
EPS dla Tarsus Pharmaceuticals, Inc. (TARS)
EPS na dzień June 2026 TTM: $-1.09
Według najnowszych raportów finansowych i ceny akcji firmy Tarsus Pharmaceuticals, Inc., obecny EPS (TTM) wynosi $-1.09. Na koniec roku 2023 firma miała EPS w wysokości $-4.62, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-2.52.
Historia EPS dla Tarsus Pharmaceuticals, Inc. od 2018 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
